Remove Bioavailability Remove Contamination Remove Manufacturing Remove Pharmacy
article thumbnail

Small molecule API: Shining a spotlight on new innovations in milling

Pharmaceutical Technology

Evidence suggests that API manufacturing is gaining in complexity, as well as sophistication, and therefore adding to the risk profile of drug development. The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment.

article thumbnail

A winning combination: The benefits of micronization and containment in a single installation

Pharmaceutical Technology

Containment challenges and opportunities High containment facilities guard against exposure to extremely potent products and cross-contamination. GlobalData’s Contract Small Molecule API Manufacturing Industry by the Numbers (2021) analyzed 2,787 small molecule API contract manufacturing facilities.